CG
SNDX icon

Cutler Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Cutler Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,300
Closed -$7K – 6284
2021
Q1 		$7K Sell
2,300
-7,200
-76% -$163K ﹤0.01% 4145
2020
Q4 		$4K Buy
+9,500
New +$197K ﹤0.01% 3829
2019
Q3 		– Sell
-2,800
Closed -$3K – 4642
2019
Q2 		$3K Buy
+2,800
New +$20.4K ﹤0.01% 3420
2018
Q4 		– Sell
-2,600
Closed -$5K – 4534
2018
Q3 		$5K Buy
+2,600
New +$18.5K ﹤0.01% 3072

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's SNDX Position: Q2 2021 in Review

Cutler Group sold out of Syndax Pharmaceuticals (SNDX) in Q2 2021, closing a stake of 1,500 shares — an estimated $33K sold.

Cutler Group first reported a position in SNDX in Q2 2018 and held it in 6 quarters. The position peaked at $33K in Q1 2021. 115 funds tracked by Wall St. Rank hold SNDX as of Q2 2021.

  • Cutler Group reported no remaining Syndax Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Cutler Group sold 1,500 Syndax Pharmaceuticals shares in Q2 2021, an estimated $33K.
  • Cutler Group first reported a position in Syndax Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • Cutler Group's Syndax Pharmaceuticals position peaked at $33K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2021.

Based on Cutler Group's 13F filing for Q2 2021, filed 19 Jul 2021.